Dr. Vimal J. Ponnezhan, MD

Dr. Ponnezhan practices at Foothill Pulmonary & Critical Care Consultants Medical Group Inc. in Pasadena, California.

Dr. Ponnezhan's NPI, 1366653354, was assigned on May 24, 2007. Dr. Ponnezhan holds California license A116214.

Dr. Ponnezhan's primary practice is Foothill Pulmonary & Critical Care Consultants Medical Group Inc., at 959 E Walnut St, Pasadena, CA 91106 in Los Angeles County. The practice phone is (626) 795-5118.

Dr. Ponnezhan's primary practice is Foothill Pulmonary & Critical Care Consultants Medical Group Inc. in Pasadena, California. Dr. Ponnezhan is also affiliated with Huntington Hospital. The medical group on file is Foothill Pulmonary and Critical Care Consultants Medical Group, Inc. Dmand AI also links Dr. Ponnezhan to 3 more hospitals, 4 hospices, 2 medical groups, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ponnezhan practices, 10 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Ponnezhan's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dmand AI has Dr. Ponnezhan's licenses on file in 2 states: California and Michigan.

CMS data shows 1,114 Medicare services from Dr. Ponnezhan across 12 procedure codes in 2024, for 344 Medicare patients. Medicare paid $148,564 for them.

CMS counts 344 Medicare patients who saw Dr. Ponnezhan in 2024. The largest group is 65 to 74, with 133 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 63% are also on Medicaid. Their average risk score is 3.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ponnezhan's median patient age at 69, with 48% women.

In 2024, Dr. Ponnezhan wrote 954 Medicare Part D claims for 189 patients. 53% of them were for generic drugs. CMS names the drug for 781 of them, across 17 drugs with 11 or more claims each, at $150,988 in total drug cost. In 2023, CMS named 505 claims across 15 drugs.

Dr. Ponnezhan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ponnezhan as offering telehealth.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Ponnezhan to 1 clinical trial. Conditions studied include Dyspnea and Signs and Symptoms, Respiratory.

CMS Open Payments shows 88 general payments to Dr. Ponnezhan from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $389.